NCT03185065View on ClinicalTrials.gov

Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis

PHASE3CompletedINTERVENTIONAL
Enrollment

141

Participants

Timeline

Start Date

October 4, 2017

Primary Completion Date

November 21, 2019

Study Completion Date

November 21, 2019

Conditions
Fatigue in Multiple Sclerosis
Interventions
DRUG

Amantadine

100 mg of amantadine increased to 200 mg of amantadine, if tolerated

DRUG

Modafinil

100 mg of modafinil increased to 200 mg of modafinil, if tolerated

DRUG

Methylphenidate

5 mg of methylphenidate uptitrated to max of 20 mg of methylphenidate, if tolerated

DRUG

Placebos

1 placebo capsule increased to max of 2 capsules twice daily

Trial Locations (2)

21287

Johns Hopkins University, Baltimore

94158

University of California San Francisco, San Francisco

All Listed Sponsors
collaborator

Patient-Centered Outcomes Research Institute

OTHER

lead

Johns Hopkins University

OTHER

NCT03185065 - Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis | Biotech Hunter | Biotech Hunter